IFNγ identified as crucial for reducing pulmonary viral loads in COVID-19, new research shows

The role of type-2 interferon (IFNγ) in antiviral immunity.

APOE4 genetic risk factors for Alzheimer’s disease associated with increased risk of subclinical atherosclerosis

Scientists at the Centro Nacional de Investigaciones Cardiovasculares in Madrid have found that one of the most potent genetic risk factors for Alzheimer disease, apolipoprotein

January 23, 2024

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC – Pharmaceutical Technology

Augtyro first received FDA approval for the treatment of adults with NSCLC in November 2023. Credits: JHVEPhoto/Shutterstock.com Zai Lab has announced that its New Drug

May 13, 2024

Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases

November 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.